Hims & Hers Health saw its shares drop approximately 4% before the market opened on Monday, following the company's announcement of a $300 million convertible senior note offering. The telehealth firm also granted initial buyers an option to purchase an additional $45 million in notes, fueling concerns among investors about potential shareholder dilution.
The stock was trading at $24.04 ahead of the opening bell, down from Friday's close of $25.05. The financing move comes just days after the company reported a wider-than-expected first-quarter net loss and a decline in gross margins, which had already weighed on investor sentiment.
Details of the Convertible Note Offering
Hims & Hers stated that the notes will mature on June 1, 2032, and will carry semi-annual interest payments. The debt is senior unsecured, meaning it ranks above certain other obligations but is not backed by specific assets. The initial purchasers have a 13-day window to acquire the additional $45 million in notes. The company has not yet set the interest rate or conversion terms, which will depend on market conditions.
The proceeds from the offering are intended to provide financial flexibility as Hims & Hers pursues its planned acquisition of Australian telehealth company Eucalyptus, which could be worth up to $1.15 billion. Additionally, the funds will support technology and fulfillment investments, as well as artificial intelligence initiatives. A portion of the proceeds will also be used for capped call transactions, which are designed to hedge against potential dilution from the convertible notes.
First-Quarter Results and Strategic Shift
The capital raise follows the company's first-quarter earnings report, which showed revenue of $608.1 million, up 4% year-over-year. However, the company posted a net loss of $92.1 million, swinging from a net income of $49.5 million in the same period last year. Gross margin fell to 65% from 73%, and adjusted EBITDA dropped to $44.3 million from $91.1 million.
Management has raised its 2026 revenue guidance to a range of $2.8 billion to $3.0 billion, with adjusted EBITDA expected between $275 million and $350 million. These projections do not include the impact of the Eucalyptus acquisition. The company is also shifting its weight-loss strategy away from lower-cost compounded GLP-1 drugs toward branded options like Novo Nordisk's Wegovy, following increased regulatory scrutiny from the FDA on compounded versions of semaglutide and tirzepatide.
Market Reaction and Analyst Views
Investors have reacted cautiously to the news, interpreting the debt sale as a sign of the company's need for capital to fund its growth ambitions. Analysts have noted that Hims & Hers is now viewed as an execution story rather than a pure growth play. Jefferies analyst Brian Tanquilut described the company as "an execution story now," while J.P. Morgan's Cory Carpenter suggested that stabilization in the weight-loss business and potential peptide legalization could create a "compelling catalyst path" in the second half of the year.
The convertible note offering is not without risks. The final terms depend on market conditions, and conversion could dilute existing shareholders if the capped call hedge does not fully offset the impact. The company also cited risks from share price volatility, interest rate changes, and regulatory approvals needed for the Eucalyptus deal.
Despite the near-term pressure on the stock, Hims & Hers remains focused on its long-term strategy of expanding its platform, investing in technology, and capitalizing on the branded weight-loss drug market. However, investors are looking for tangible evidence of profitability and sustainable growth before regaining confidence.
